Nicorette

(redirected from Habitrol)
Also found in: Wikipedia.

Nicorette

(nĭk′ə-rĕt′)
A trademark for an over-the-counter preparation of chewing gum containing nicotine, used to treat nicotine dependence.

Nicorette

a trademark for a nicotine resin complex (nicotine polacrilex).

Nicorette®

See Nicotine gum.

Nicorette

A brand name for under-the-tongue tablets, chewing gum or artificial cigarettes containing NICOTINE. This is intended to make the abandonment of cigarette smoking a less painful procedure. Such measures are no real substitute for simple resolution and the acceptance of a brief period of suffering.
References in periodicals archive ?
At presently, GSK has its own nicotine replacement patch, Nicoderm CQ, a direct competitor of Habitrol.
The contest is funded by the Government of Ontario with prize support provided by the makers of Thrive and Habitrol quit-smoking aids.
2) Transdermal patch formulation previously marketed as Habitrol.
There's the V-Chip, the Habitrol nicotine patch, an electronic hearing implant, and Google.
The plaintiff's federal appellate brief in a Habitrol case where the Oklahoma trial court held that that an exception to the learned intermediary rule exists where the FDA requires direct consumer warnings on prescription products.
TABLE Transdermal Patch Comparison Dosage Trade Names Dosing Forms Available Habitrol 21 mg/day for 4 weeks, then 7,14, and 21 14 mg/day for 2 weeks, then mg/day patches 7 mg/day for 2 weeks Nicoderm, 21 mg/day for 6 weeks, then 7, 14, and 21 Nicoderm CQ 14 mg/day for 2 weeks, then mg/day patches Clear Nicoderm 7 mg/day for 2 weeks CQ Nicotrol 15 mg/16 hrs for 6 weeks 15 mg/16 hrs patch
Following the plaintiff's reasoning, the Oklahoma Supreme Court held that the FDA mandate of a direct patient warning created an exception to the learned intermediary doctrine, and imposed a common law duty on the Habitrol manufacturer to provide an adequate warning to the patient directly.
Novartis has decided to divest Habitrol, its private label nicotine replacement therapy (NRT) transdermal patch business in the US, which was laid as a condition to gain FTC approval for the consumer healthcare JV.
These breakthroughs include the development of the Google search engine, Habitrol Nicotine patch, treatments for neglected diseases, cancer drug Taxol, and the V-chip -- all of which might not exist today if not for the support of academic technology transfer.
Sponsorship tools available to physicians on the Web include a smoking-cessation support program from Novartis, maker of the Habitrol nicotine patch.
In addition to a personal coach, the program features customized programming, support and education and discounts for supportive programs such as Weight Watchers and Habitrol Nicotine Replacement Therapy.
The company also signed an agreement for Tobacco Solutions, an eight-week tobacco cessation program offering deep discounts on the Novartis Habitrol Transdermal system, "the patch," and behavioral support through educational materials and toll-free counseling support five days a week.